Assessment of Disease Severity in Parkinsonism with Fluorine-18-Fluorodeoxyglucose and PET

Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identify an abnormal regional metabolic covariance pattern in Parkinson's disease (PD). To examine the potential use of this covariance pattern as a metabolic imaging marker for PD, we describe the Topographic Profile Rating (TPR),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 1995-03, Vol.36 (3), p.378-383
Hauptverfasser: Eidelberg, David, Moeller, James R, Ishikawa, Tatsuya, Dhawan, Vijay, Spetsieris, Phoebe, Chaly, Thomas, Robeson, William, Dahl, J. Robert, Margouleff, Donald
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 383
container_issue 3
container_start_page 378
container_title The Journal of nuclear medicine (1978)
container_volume 36
creator Eidelberg, David
Moeller, James R
Ishikawa, Tatsuya
Dhawan, Vijay
Spetsieris, Phoebe
Chaly, Thomas
Robeson, William
Dahl, J. Robert
Margouleff, Donald
description Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identify an abnormal regional metabolic covariance pattern in Parkinson's disease (PD). To examine the potential use of this covariance pattern as a metabolic imaging marker for PD, we describe the Topographic Profile Rating (TPR), which is a method for calculating subject scores for this pattern in individual PD patients. We then assess the relationship between these metabolic measures and objective independent disease severity ratings. Two independent groups of PD patients were studied with FDG-PET. Group A consisted of 23 patients (mean age 60.2 +/- 12.2; mean Hoehn and Yahr stages 2.4 +/- 1.3) and Group B had 14 patients (mean age 49.0 +/- 12.1; mean Hoehn and Yahr stage 3.2 +/- 1.2). The regional cerebral metabolic rates for glucose (rCMRGlc) in all patients in each group were measured. TPR was used to calculate subject scores for the disease-related covariance pattern on a patient-by-patient basis. In both PD patient groups, subject scores correlated with Hoehn and Yahr disease severity ratings (Group A: r = 0.59, p < 0.004; Group B: 0.57, p < 0.04), quantitative ratings for bradykinesia (Group A: r = 0.63, p < 0.002; Group B: r = 0.61, p < 0.03), rigidity (Group A: r = 0.59, p < 0.004; Group B: r = 0.59, p < 0.04), but not with tremor. These findings indicate that regional metabolic covariance patterns are robust imaging markers of disease severity. FDG-PET may be useful clinically in assessing parkinsonian disability and disease progression.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77169926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77169926</sourcerecordid><originalsourceid>FETCH-LOGICAL-h266t-e82cf3a0891cd7c27476172c78073455b7c1a70090c33a729e02d536d4319a2f3</originalsourceid><addsrcrecordid>eNpFkEtLw0AUhQdRaq3-BCELcReYR-aRZamtCgUL1o2bMJ3ctFOTmTqTWPvvrRp0dQ-c75wL5wQNCWc85ULIUzTERJCUc8zP0UWMW4yxUEoN0EAqlWW5GqLXcYwQYwOuTXyV3NkIOkLyDB8QbHtIrEsWOrxZF72zsUn2tt0ks7rzwTpIiUp_tC_Bfx7WdWf8MaxdmSymy0t0Vuk6wlV_R-hlNl1OHtL50_3jZDxPN1SINgVFTcU0VjkxpTRUZlIQSY1UWLKM85U0REuMc2wY05LmgGnJmSgzRnJNKzZCt7-9u-DfO4ht0dhooK61A9_FQkoi8pyKI3jdg92qgbLYBdvocCj6MY7-Te_raHRdBe2MjX8YyzLFM_r_b2PXm70NULjO1KDDd-fWNUwUrGBSsS_NGnV_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77169926</pqid></control><display><type>article</type><title>Assessment of Disease Severity in Parkinsonism with Fluorine-18-Fluorodeoxyglucose and PET</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Eidelberg, David ; Moeller, James R ; Ishikawa, Tatsuya ; Dhawan, Vijay ; Spetsieris, Phoebe ; Chaly, Thomas ; Robeson, William ; Dahl, J. Robert ; Margouleff, Donald</creator><creatorcontrib>Eidelberg, David ; Moeller, James R ; Ishikawa, Tatsuya ; Dhawan, Vijay ; Spetsieris, Phoebe ; Chaly, Thomas ; Robeson, William ; Dahl, J. Robert ; Margouleff, Donald</creatorcontrib><description><![CDATA[Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identify an abnormal regional metabolic covariance pattern in Parkinson's disease (PD). To examine the potential use of this covariance pattern as a metabolic imaging marker for PD, we describe the Topographic Profile Rating (TPR), which is a method for calculating subject scores for this pattern in individual PD patients. We then assess the relationship between these metabolic measures and objective independent disease severity ratings. Two independent groups of PD patients were studied with FDG-PET. Group A consisted of 23 patients (mean age 60.2 +/- 12.2; mean Hoehn and Yahr stages 2.4 +/- 1.3) and Group B had 14 patients (mean age 49.0 +/- 12.1; mean Hoehn and Yahr stage 3.2 +/- 1.2). The regional cerebral metabolic rates for glucose (rCMRGlc) in all patients in each group were measured. TPR was used to calculate subject scores for the disease-related covariance pattern on a patient-by-patient basis. In both PD patient groups, subject scores correlated with Hoehn and Yahr disease severity ratings (Group A: r = 0.59, p < 0.004; Group B: 0.57, p < 0.04), quantitative ratings for bradykinesia (Group A: r = 0.63, p < 0.002; Group B: r = 0.61, p < 0.03), rigidity (Group A: r = 0.59, p < 0.004; Group B: r = 0.59, p < 0.04), but not with tremor. These findings indicate that regional metabolic covariance patterns are robust imaging markers of disease severity. FDG-PET may be useful clinically in assessing parkinsonian disability and disease progression.]]></description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>PMID: 7884498</identifier><language>eng</language><publisher>Reston, VA: Soc Nuclear Med</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Brain - diagnostic imaging ; Deoxyglucose - analogs &amp; derivatives ; Female ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Middle Aged ; Nervous system ; Parkinson Disease - diagnostic imaging ; Radionuclide investigations ; Severity of Illness Index ; Tomography, Emission-Computed</subject><ispartof>The Journal of nuclear medicine (1978), 1995-03, Vol.36 (3), p.378-383</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3448542$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7884498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eidelberg, David</creatorcontrib><creatorcontrib>Moeller, James R</creatorcontrib><creatorcontrib>Ishikawa, Tatsuya</creatorcontrib><creatorcontrib>Dhawan, Vijay</creatorcontrib><creatorcontrib>Spetsieris, Phoebe</creatorcontrib><creatorcontrib>Chaly, Thomas</creatorcontrib><creatorcontrib>Robeson, William</creatorcontrib><creatorcontrib>Dahl, J. Robert</creatorcontrib><creatorcontrib>Margouleff, Donald</creatorcontrib><title>Assessment of Disease Severity in Parkinsonism with Fluorine-18-Fluorodeoxyglucose and PET</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description><![CDATA[Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identify an abnormal regional metabolic covariance pattern in Parkinson's disease (PD). To examine the potential use of this covariance pattern as a metabolic imaging marker for PD, we describe the Topographic Profile Rating (TPR), which is a method for calculating subject scores for this pattern in individual PD patients. We then assess the relationship between these metabolic measures and objective independent disease severity ratings. Two independent groups of PD patients were studied with FDG-PET. Group A consisted of 23 patients (mean age 60.2 +/- 12.2; mean Hoehn and Yahr stages 2.4 +/- 1.3) and Group B had 14 patients (mean age 49.0 +/- 12.1; mean Hoehn and Yahr stage 3.2 +/- 1.2). The regional cerebral metabolic rates for glucose (rCMRGlc) in all patients in each group were measured. TPR was used to calculate subject scores for the disease-related covariance pattern on a patient-by-patient basis. In both PD patient groups, subject scores correlated with Hoehn and Yahr disease severity ratings (Group A: r = 0.59, p < 0.004; Group B: 0.57, p < 0.04), quantitative ratings for bradykinesia (Group A: r = 0.63, p < 0.002; Group B: r = 0.61, p < 0.03), rigidity (Group A: r = 0.59, p < 0.004; Group B: r = 0.59, p < 0.04), but not with tremor. These findings indicate that regional metabolic covariance patterns are robust imaging markers of disease severity. FDG-PET may be useful clinically in assessing parkinsonian disability and disease progression.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Brain - diagnostic imaging</subject><subject>Deoxyglucose - analogs &amp; derivatives</subject><subject>Female</subject><subject>Fluorine Radioisotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nervous system</subject><subject>Parkinson Disease - diagnostic imaging</subject><subject>Radionuclide investigations</subject><subject>Severity of Illness Index</subject><subject>Tomography, Emission-Computed</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLw0AUhQdRaq3-BCELcReYR-aRZamtCgUL1o2bMJ3ctFOTmTqTWPvvrRp0dQ-c75wL5wQNCWc85ULIUzTERJCUc8zP0UWMW4yxUEoN0EAqlWW5GqLXcYwQYwOuTXyV3NkIOkLyDB8QbHtIrEsWOrxZF72zsUn2tt0ks7rzwTpIiUp_tC_Bfx7WdWf8MaxdmSymy0t0Vuk6wlV_R-hlNl1OHtL50_3jZDxPN1SINgVFTcU0VjkxpTRUZlIQSY1UWLKM85U0REuMc2wY05LmgGnJmSgzRnJNKzZCt7-9u-DfO4ht0dhooK61A9_FQkoi8pyKI3jdg92qgbLYBdvocCj6MY7-Te_raHRdBe2MjX8YyzLFM_r_b2PXm70NULjO1KDDd-fWNUwUrGBSsS_NGnV_</recordid><startdate>19950301</startdate><enddate>19950301</enddate><creator>Eidelberg, David</creator><creator>Moeller, James R</creator><creator>Ishikawa, Tatsuya</creator><creator>Dhawan, Vijay</creator><creator>Spetsieris, Phoebe</creator><creator>Chaly, Thomas</creator><creator>Robeson, William</creator><creator>Dahl, J. Robert</creator><creator>Margouleff, Donald</creator><general>Soc Nuclear Med</general><general>Society of Nuclear Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19950301</creationdate><title>Assessment of Disease Severity in Parkinsonism with Fluorine-18-Fluorodeoxyglucose and PET</title><author>Eidelberg, David ; Moeller, James R ; Ishikawa, Tatsuya ; Dhawan, Vijay ; Spetsieris, Phoebe ; Chaly, Thomas ; Robeson, William ; Dahl, J. Robert ; Margouleff, Donald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h266t-e82cf3a0891cd7c27476172c78073455b7c1a70090c33a729e02d536d4319a2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Brain - diagnostic imaging</topic><topic>Deoxyglucose - analogs &amp; derivatives</topic><topic>Female</topic><topic>Fluorine Radioisotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nervous system</topic><topic>Parkinson Disease - diagnostic imaging</topic><topic>Radionuclide investigations</topic><topic>Severity of Illness Index</topic><topic>Tomography, Emission-Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eidelberg, David</creatorcontrib><creatorcontrib>Moeller, James R</creatorcontrib><creatorcontrib>Ishikawa, Tatsuya</creatorcontrib><creatorcontrib>Dhawan, Vijay</creatorcontrib><creatorcontrib>Spetsieris, Phoebe</creatorcontrib><creatorcontrib>Chaly, Thomas</creatorcontrib><creatorcontrib>Robeson, William</creatorcontrib><creatorcontrib>Dahl, J. Robert</creatorcontrib><creatorcontrib>Margouleff, Donald</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eidelberg, David</au><au>Moeller, James R</au><au>Ishikawa, Tatsuya</au><au>Dhawan, Vijay</au><au>Spetsieris, Phoebe</au><au>Chaly, Thomas</au><au>Robeson, William</au><au>Dahl, J. Robert</au><au>Margouleff, Donald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of Disease Severity in Parkinsonism with Fluorine-18-Fluorodeoxyglucose and PET</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>1995-03-01</date><risdate>1995</risdate><volume>36</volume><issue>3</issue><spage>378</spage><epage>383</epage><pages>378-383</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract><![CDATA[Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identify an abnormal regional metabolic covariance pattern in Parkinson's disease (PD). To examine the potential use of this covariance pattern as a metabolic imaging marker for PD, we describe the Topographic Profile Rating (TPR), which is a method for calculating subject scores for this pattern in individual PD patients. We then assess the relationship between these metabolic measures and objective independent disease severity ratings. Two independent groups of PD patients were studied with FDG-PET. Group A consisted of 23 patients (mean age 60.2 +/- 12.2; mean Hoehn and Yahr stages 2.4 +/- 1.3) and Group B had 14 patients (mean age 49.0 +/- 12.1; mean Hoehn and Yahr stage 3.2 +/- 1.2). The regional cerebral metabolic rates for glucose (rCMRGlc) in all patients in each group were measured. TPR was used to calculate subject scores for the disease-related covariance pattern on a patient-by-patient basis. In both PD patient groups, subject scores correlated with Hoehn and Yahr disease severity ratings (Group A: r = 0.59, p < 0.004; Group B: 0.57, p < 0.04), quantitative ratings for bradykinesia (Group A: r = 0.63, p < 0.002; Group B: r = 0.61, p < 0.03), rigidity (Group A: r = 0.59, p < 0.004; Group B: r = 0.59, p < 0.04), but not with tremor. These findings indicate that regional metabolic covariance patterns are robust imaging markers of disease severity. FDG-PET may be useful clinically in assessing parkinsonian disability and disease progression.]]></abstract><cop>Reston, VA</cop><pub>Soc Nuclear Med</pub><pmid>7884498</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0161-5505
ispartof The Journal of nuclear medicine (1978), 1995-03, Vol.36 (3), p.378-383
issn 0161-5505
1535-5667
language eng
recordid cdi_proquest_miscellaneous_77169926
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adult
Aged
Biological and medical sciences
Brain - diagnostic imaging
Deoxyglucose - analogs & derivatives
Female
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
Nervous system
Parkinson Disease - diagnostic imaging
Radionuclide investigations
Severity of Illness Index
Tomography, Emission-Computed
title Assessment of Disease Severity in Parkinsonism with Fluorine-18-Fluorodeoxyglucose and PET
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A40%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20Disease%20Severity%20in%20Parkinsonism%20with%20Fluorine-18-Fluorodeoxyglucose%20and%20PET&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Eidelberg,%20David&rft.date=1995-03-01&rft.volume=36&rft.issue=3&rft.spage=378&rft.epage=383&rft.pages=378-383&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E77169926%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77169926&rft_id=info:pmid/7884498&rfr_iscdi=true